The Green Lab: Rethinking Research from the Bench Up

A laboratory is not an obvious symbol of environmental excess. The image it conjures — meticulous, precise, controlled — suggests restraint rather than waste. The reality is different. Labs consume ten times more energy than office spaces and use four times more water. The chemical industry generates 5.4 billion kilograms of plastic waste annually, much of it from the single-use plastics — pipette tips, specimen tubes, petri dishes — that are the infrastructure of daily laboratory work. A single clinical trial produces around 180 tonnes of CO₂ per year. If clinical science were treated as a country, it would rank as the 40th largest CO₂ emitter in the world, above Nigeria and Bangladesh.

These figures come from a field of research that has grown substantially over the past five years. The 2026 review of sustainability management controls in healthcare organisations, published in the journal Environmental and Sustainability Management, documented that peak years for academic publications on the subject were 2024 and 2025 — a reflection of how recently the scientific community itself turned systematic attention toward its own footprint. The CASCADES playbook, published in ScienceDirect in April 2025, represents the first national-level guidance document for clinical laboratories seeking to improve environmental sustainability — a baseline that, by its existence, reveals how new the formalisation of these practices remains.

Green Chemistry: Redesigning the Molecule

The most structurally significant change in pharmaceutical R&D sustainability is occurring at the level of chemical synthesis itself. Green chemistry — a discipline built on twelve principles including waste prevention, atom economy, safer solvents, and designing for degradation — is being integrated into drug discovery workflows at a pace and scale that would have been difficult to imagine a decade ago.

AstraZeneca has moved furthest in embedding these principles into its R&D culture. The company’s green chemistry programme replaces conventional chemical processes with biocatalysis — the use of enzymes, microbes, or plant extracts to drive reactions that previously required toxic solvents or energy-intensive conditions. Biocatalysts operate at ambient temperature and pressure, generate minimal waste, and in many cases produce cleaner stereochemical outcomes that reduce the number of synthetic steps required to reach a target compound. Fewer steps mean less solvent, less energy, and less waste — the sustainability gains and the efficiency gains are the same intervention.

AstraZeneca also introduced a sticker system — green, amber, or red labels on laboratory equipment indicating whether instruments are safe to shut down after use — that has produced tangible energy reductions across its research sites through simple behavioural nudges. It is an illustration of a broader principle: in laboratory sustainability, systemic infrastructure investment and individual practice change are both necessary, and neither is sufficient alone.

The My Green Lab certification programme, now encompassing more than 4,000 certified labs globally, provides a structured framework for benchmarking and improving laboratory environmental performance. Benchmarking analysis within the programme has documented that labs of comparable size and function can differ in emissions by a factor of 5.5 — a spread that reveals how much performance improvement is achievable within existing infrastructure, without capital replacement.

Clinical Trial Decarbonisation: Roche’s Industrial Approach

Clinical trials generate emissions across multiple vectors: energy consumed in coordinating centres, patient and investigator travel, material distribution and delivery, and the operational footprint of the trial sites themselves. As trial complexity has increased and global sites have proliferated, emissions have grown alongside. For large Phase 3 programmes spanning dozens of countries, the carbon impact is non-trivial.

Roche has taken the most systematic approach to this problem in the industry. The company’s integrated Life Cycle Carbon Tool (iLCCT), deployed in partnership with contract research organisations and suppliers, enables clinical development teams to calculate the carbon footprint of trial design and execution decisions before they are made — shifting sustainability from a retrospective reporting exercise to a prospective design input. Beginning in 2025, Roche committed to reporting total emissions per trial for all Phase 2 and 3 studies launched from that year forward. In 2026, the initiative enters a new phase: using calculated footprints to identify emission hotspots and implement targeted reduction efforts.

That level of specificity — trial-by-trial carbon accounting, supplier-engaged shared reporting, prospective design tools — sets a standard that the broader industry has not yet matched. Seven major pharmaceutical companies, including Roche, updated their joint supplier sustainability targets in November 2025, raising expectations for emissions reductions across the pharmaceutical value chain. The collective action that My Green Lab identified as most effective is, in this case, being formalised through multi-company supplier commitments rather than left to bilateral negotiation.

Decarbonising the Supply Chain — and Why It Is Hard

The pharmaceutical supply chain is global, complex, and temperature-sensitive. Active pharmaceutical ingredients (APIs) are predominantly manufactured in India and China, often in facilities that rely on coal-powered electricity. Cold chain logistics for biological medicines — including the monoclonal antibodies that now represent a major share of pharmaceutical revenues — require continuous refrigeration across thousands of miles and multiple transport modes. Packaging generates substantial plastic and paper waste.

Oliver Wyman’s analysis of the sector’s net-zero gap identified four structural barriers: difficulty measuring Scope 3 due to limited supplier transparency; inadequate financing and risk management frameworks for decarbonisation investments; inconsistent carbon accounting methodologies; and a cultural gap in which decarbonisation is not yet embedded as a core strategic priority throughout the leadership chain. The same analysis noted that by working directly with suppliers, companies can theoretically achieve net zero with 60 to 70% abatement at cumulatively zero cost — meaning the supply chain efficiency gains pay for themselves. The incentive structure exists. The implementation capacity does not yet match it.

A Sector That Must Solve Its Own Contradiction

The companies best positioned for the next decade of sustainable pharmaceutical R&D are those that have moved beyond treating the laboratory as exempt from environmental accountability — and have begun treating sustainability as a design constraint from the first stage of drug discovery through the last stage of clinical development. The benchmarking evidence suggests that the performance gap between leaders and laggards is not primarily a gap in intention or resources. It is a gap in specificity: the leaders have quantified their footprint at the level of individual trials and lab operations, set interim targets, and built accountability structures. The rest of the industry will, under mounting regulatory and investor pressure, have to follow.

Author

Bernice Lottering

Related Post

North America

EirGenix Strengthens U.S. East Coast Presence, Leveraging DCAT Week and TCA Multi-City Events to Expand Global CDMO Opportunities

2026-03-25

go prime

Generative AI Lowers the Drug Discovery Barrier — Can Smaller Biotechs Finally Rival Big Pharma?

2025-11-03

Neuroscience & Mental Health

SEQENS: A Strategic Blueprint for Supply Chain Success in Pharmaceuticals

2025-01-29